<DOC>
	<DOCNO>NCT02932345</DOCNO>
	<brief_summary>The primary objective describe genomic profile long-term survivor , especially find potential genomic prognosis and/or predictive factor gefitinib long-term efficacy compare rapid PD patient</brief_summary>
	<brief_title>Gefitinib Long-term Survivor Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>For inclusion longterm survivor group , study subject must fulfil follow criterion time screening : 1 . Provision inform consent EC approve inform consent waiver prior study specific procedures 2 . Histological cytological confirm locally advanced NSCLC ( stage III B ) metastatic ( stage IV ) NSCLC , amenable curative surgery radiotherapy 3 . EGFR mutation positive 4 . Patients continuously receive gefitinib least 3 year without evidence PD 5 . Patients OS ≥ 5 year NSCLC diagnosis prefer 6 . Collect archival tumour tissue gefitinib treatment ( blood rebiopsy tumour tissue optional ) ; tumor tissue sample requirement : 1 ) slice requirement : &gt; 1 cm2 , thickness 45 μm , ≥ 15 slice . , whole FFPE block ; 2 ) tumor percentage &gt; 20 % necrosis &lt; 30 % pathology QC . For inclusion rapid PD group , study subject must fulfil follow criterion : 1 . Provision inform consent EC approve inform consent waiver prior study specific procedures 2 . Histological cytological confirm locally advanced NSCLC ( stage III B ) metastatic ( stage IV ) NSCLC , amenable curative surgery radiotherapy 3 . EGFR mutation positive 4 . Patients undergone PD gefitinib treatment≤3 month ( Rapid PD ) 5 . Collect archival tumour tissue gefitinib treatment ( blood rebiopsy tumour tissue sample optional ) ; tumor tissue sample requirement : 1 ) slice requirement : &gt; 1 cm2 , thickness 45 μm , ≥ 15 slice . , whole FFPE block ; 2 ) tumor percentage &gt; 20 % necrosis &lt; 30 % pathology QC . For active patient , must enter study follow exclusion criterion fulfil 1 . Patients disagree participate study . For terminated patient , must enter study follow exclusion criterion fulfil 1 . Patients whose medical objection record use exist data medical practice scientific research .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EGFR mutation ; non-small-cell lung cancer ;</keyword>
</DOC>